Antiretroviral therapy (ART) prevents HIV from multiplying by targeting different stages of the viral life cycle. When treatment works effectively, viral levels decrease, allowing the immune system to function more effectively. People who maintain an undetectable viral load through consistent treatment do not sexually transmit HIV. This principle is commonly described as Undetectable Equals Untransmittable (U=U).
Injectable therapy is an alternative to daily oral medication for certain individuals. Long-acting injectable treatments, including cabotegravir and rilpivirine, are administered by healthcare professionals at scheduled intervals. These medications help maintain antiviral activity between appointments.
However, injectable treatment is not suitable for everyone. Eligibility generally depends on treatment history, viral suppression status, previous drug resistance, and other clinical considerations.
Viral load testing: Measures the amount of HIV in the bloodstream and evaluates treatment response.
CD4 cell monitoring: Helps assess immune system health and changes over time.
Injectable medication: Provides long-acting antiretroviral treatment without requiring daily oral doses.
Treatment eligibility: Healthcare professionals evaluate medical history, resistance information, and current viral suppression.
U=U principle: Sustained viral suppression prevents sexual transmission of HIV.
Managing injectable HIV therapy requires careful planning, regular medical appointments, and consistent monitoring. Long-acting cabotegravir and rilpivirine are commonly administered as separate intramuscular injections. Depending on the prescribed regimen, injections may be given monthly or every two months after the recommended initiation process.
Before starting injectable treatment, healthcare professionals review the patient's medical history, current medications, previous antiretroviral treatments, and possible drug resistance. This assessment helps determine whether the treatment is appropriate.
One important consideration is maintaining the injection schedule. Delayed or missed injections can allow medication concentrations to decrease, potentially increasing the risk of viral rebound and drug resistance. If an appointment cannot be attended, patients should contact their healthcare provider to discuss the appropriate arrangements.
Clinical monitoring also helps identify side effects and evaluate whether viral suppression continues. Injection-site reactions, including pain, swelling, redness, and tenderness, are among the commonly reported side effects.
Scheduled appointments: Follow the prescribed injection timetable to maintain medication coverage.
Viral load assessments: Monitor HIV levels to identify changes in treatment response.
Medication reviews: Check for interactions with prescription medicines and other treatments.
Side effect evaluation: Discuss persistent injection-site reactions or other unexpected symptoms with healthcare professionals.
Missed injection management: Follow medical advice regarding replacement injections or temporary oral treatment when necessary.
Ongoing follow-up: Maintain regular clinical assessments to evaluate treatment effectiveness and overall health.
Healthcare professionals may recommend additional testing when viral load increases or treatment response becomes uncertain. Resistance testing can help identify whether HIV has developed resistance to particular medications. If treatment failure is suspected, the healthcare team evaluates alternative antiretroviral options based on individual clinical findings.
Regular communication between patients and healthcare professionals supports informed treatment decisions and helps maintain continuity of HIV care.